We are live on ! Find out more
KROS icon

Keros Therapeutics
KROS

83 hedge funds and large institutions have $887M invested in Keros Therapeutics in 2021 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 31 increasing their positions, 24 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

29% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 24

15% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 13

2% more funds holding

Funds holding: 81 → 83 (+2)

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

8.01% less ownership

Funds ownership: 79.39% → 71.38% (-8%)

21% less capital invested

Capital invested by funds: $1.13B → $887M (-$242M)

Holders
83
Holders Change
+2
Holders Change %
+2.47%
% of All Funds
1.46%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.07%
New
15
Increased
31
Reduced
24
Closed
13
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CCM
Consonance Capital Management
New York
+$21.1M
2
State Street
State Street
Massachusetts
+$18.9M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$18M
4
OM
Opaleye Management
Massachusetts
+$9.98M
5
FFM
Fairmount Funds Management
Pennsylvania
+$6.93M

Top Sellers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
-$132M
2
LGM
Logos Global Management
California
-$31.7M
3
VA
VR Adviser
New York
-$19M
4
Citadel Advisors
Citadel Advisors
Florida
-$8.95M
5
Goldman Sachs
Goldman Sachs
New York
-$7.45M
Name Holding Trade Value Shares
Change 		Change in
Stake
KCM
26
Kennedy Capital Management
Missouri
$4.18M +$4.31M +67,980 New
Charles Schwab
27
Charles Schwab
California
$3.59M +$163K +2,577 +5%
Bank of New York Mellon
28
Bank of New York Mellon
New York
$2.63M -$7.86K -124 -0.3%
Citigroup
29
Citigroup
New York
$2.63M +$2.5M +39,391 +1,192%
Rafferty Asset Management
30
Rafferty Asset Management
New York
$2.1M +$1.96M +30,951 +1,005%
AI
31
Atom Investors
Texas
$1.72M -$1.4M -22,096 -44%
EP
32
Eversept Partners
New York
$1.7M +$1.75M +27,631 New
California Public Employees Retirement System
33
California Public Employees Retirement System
California
$1.62M -$155K -2,452 -9%
D.E. Shaw & Co
34
D.E. Shaw & Co
New York
$1.61M -$1.84M -29,060 -53%
AS
35
Altshuler Shaham
Israel
$1.39M – – –
Swiss National Bank
36
Swiss National Bank
Switzerland
$1.27M – – –
California State Teachers Retirement System (CalSTRS)
37
California State Teachers Retirement System (CalSTRS)
California
$1.23M +$13.1K +207 +1%
State of Wisconsin Investment Board
38
State of Wisconsin Investment Board
Wisconsin
$1.1M -$12.7K -200 -1%
SSA
39
Schonfeld Strategic Advisors
New York
$1.05M +$1.08M +17,046 New
UBS Group
40
UBS Group
Switzerland
$958K +$970K +15,318 +6,152%
Bank of America
41
Bank of America
North Carolina
$892K +$785K +12,388 +590%
RhumbLine Advisers
42
RhumbLine Advisers
Massachusetts
$842K +$4.05K +64 +0.5%
AllianceBernstein
43
AllianceBernstein
Tennessee
$837K -$57K -900 -6%
New York State Common Retirement Fund
44
New York State Common Retirement Fund
New York
$732K +$50.7K +800 +7%
Deutsche Bank
45
Deutsche Bank
Germany
$593K -$50.2K -792 -8%
Two Sigma Investments
46
Two Sigma Investments
New York
$522K -$1.01M -15,999 -65%
Manulife (Manufacturers Life Insurance)
47
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$466K -$9.63K -152 -2%
UBS AM
48
UBS AM
Illinois
$431K +$57K +900 +15%
ProShare Advisors
49
ProShare Advisors
Maryland
$416K +$18.6K +293 +5%
JP Morgan Chase
50
JP Morgan Chase
New York
$393K +$35.2K +555 +10%
1
2
3 4

KROS Hedge Fund Activity: Q1 2021 in Review

83 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Keros Therapeutics (KROS) for Q1 2021, worth a combined $887M — down 21% from $1.13B a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new KROS positions and 13 closed out — a net gain of 2 holders — while 31 added to existing stakes and 24 trimmed.

The largest buyer was Consonance Capital Management, adding an estimated $21.1M. The largest seller was RA Capital Management, exiting entirely with an estimated $132M sold.

  • 83 institutional investors held Keros Therapeutics (KROS) as of Q1 2021, up from 81 in Q4 2020.
  • Funds reported $887M of Keros Therapeutics stock for Q1 2021, down 21% quarter-over-quarter.
  • 15 funds opened new Keros Therapeutics positions in Q1 2021 and 13 closed out, a net change of +2 holders.
  • The largest Keros Therapeutics buyer in Q1 2021 was Consonance Capital Management, an estimated $21.1M added.
  • The largest Keros Therapeutics seller in Q1 2021 was RA Capital Management, an estimated $132M sold.

Based on aggregated 13F filings for Q1 2021.